A complete regimen

DELSTRIGO®: A complete regimen1

Dosing considerations and testing

DELSTRIGO®: A complete regimen with one-tablet, once-daily dosing1,*

DELSTRIGO® is a fixed-dose combination product containing 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of TDF.1

Due to the presence of lamivudine and TDF, test for hepatitis B virus infection prior to or when initiating DELSTRIGO®.1

Due to the presence of TDF, assess all patients for creatinine clearance, prior to and periodically during treatment. Patients at risk of renal dysfunction should additionally be tested for serum phosphorus, urine glucose, and urine protein.1

Convenient Dosing

Can be taken with or without food1

A complete regimen of 1 tablet once daily1

Dosage Adjustments

Patients ≥65 years old: No dose adjustment is required in patients ≥65 years old but data is limited. Special care is advised due to age-associated changes such as decreases in renal function.1

Renal impairment: Patients with estimated creatinine clearance <50 mL/min should not receive DELSTRIGO®.1

Hepatic impairment: No dose adjustment for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and it is not known whether exposure to doravirine will increase in these patients, therefore caution should be exercised.1

Co-administration with rifabutin: One tablet of PIFELTRO® should be taken approximately 12 hours after the DELSTRIGO® dose.1

Co-administration with other moderate CYP3A inducers: Co-administration has not been evaluated and should be avoided. If co-administration cannot be avoided, one tablet of PIFELTRO® should be taken approximately 12 hours after the DELSTRIGO® dose.1

Price

$28.79/tablet†

* Please consult Product Monograph for complete dosing information.
† Excludes mark-up and dispensing fee.
TDF=tenofovir disoproxil fumarate

Reference: 1. DELSTRIGO® Product Monograph. Merck Canada Inc. December 10, 2024.

CA-DOR-00155